StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$93.47−4.16 (-4.26%)

Close on Nov 20, 2026Market cap $8.24BP/E –Yield –

Spyre Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Spyre Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$201.34M. For fiscal 2025 it was -$209.56M. The highest annual figure on record is -$8.90M in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$209.56M–
FY2024Dec 31, 2024-$208.57M–
FY2023Dec 31, 2023-$242.30M–
FY2022Dec 31, 2022-$84.78M–
FY2021Dec 31, 2021-$65.65M–
FY2020Dec 31, 2020-$81.48M–
FY2019Dec 31, 2019-$80.33M–
FY2018Dec 31, 2018-$45.46M–
FY2017Dec 31, 2017-$27.68M–
FY2016Dec 31, 2016-$21.91M–
FY2015Dec 31, 2015-$11.32M–
FY2014Dec 31, 2014-$8.90M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$41.64M–
Q1 FY2026Mar 31, 2026-$45.64M–
Q4 FY2025Dec 31, 2025-$57.17M–
Q3 FY2025Sep 30, 2025-$56.89M–
Q2 FY2025Jun 30, 2025-$41.94M–
Q1 FY2025Mar 31, 2025-$53.57M–
Q4 FY2024Dec 31, 2024-$61.25M–
Q3 FY2024Sep 30, 2024-$55.39M–
Q2 FY2024Jun 30, 2024-$44.15M–
Q1 FY2024Mar 31, 2024-$47.77M–
Q4 FY2023Dec 31, 2023-$45.91M–
Q3 FY2023Sep 30, 2023-$18.34M–
Q2 FY2023Jun 30, 2023-$159.25M–
Q1 FY2023Mar 31, 2023-$18.81M–
Q4 FY2022Dec 31, 2022-$19.16M–
Q3 FY2022Sep 30, 2022-$18.76M–
Q2 FY2022Jun 30, 2022-$22.42M–
Q1 FY2022Mar 31, 2022-$24.44M–
Q4 FY2021Dec 31, 2021-$20.44M–
Q3 FY2021Sep 30, 2021-$20.29M–
Q2 FY2021Jun 30, 2021-$6.71M–
Q1 FY2021Mar 31, 2021-$18.21M–
Q4 FY2020Dec 31, 2020-$22.78M–
Q3 FY2020Sep 30, 2020-$18.12M–
Q2 FY2020Jun 30, 2020-$21.56M–
Q1 FY2020Mar 31, 2020-$19.02M–
Q4 FY2019Dec 31, 2019-$21.91M–
Q3 FY2019Sep 30, 2019-$22.15M–
Q2 FY2019Jun 30, 2019-$18.62M–
Q1 FY2019Mar 31, 2019-$17.66M–
Q4 FY2018Dec 31, 2018-$15.31M–
Q3 FY2018Sep 30, 2018-$12.24M–
Q2 FY2018Jun 30, 2018-$9.67M–
Q1 FY2018Mar 31, 2018-$8.25M–
Q4 FY2017Dec 31, 2017-$6.63M–
Q3 FY2017Sep 30, 2017-$8.00M–
Q2 FY2017Jun 30, 2017-$6.72M–
Q1 FY2017Mar 31, 2017-$6.33M–
Q4 FY2016Dec 31, 2016-$5.54M–
Q3 FY2016Sep 30, 2016-$6.30M–

More Spyre Therapeutics figures

See a number that looks wrong?